
X
MacroGenics’ HER2 breast cancer drug Margenza approved in US
https://pharmaphorum.com/news/macrogenics-her2-breast-cancer-drug-margenza-approved-in-us/
Tesaro and Puma are potential takeover targets
Neratinib can be used to reduce risk of disease returning.
ASCO serves up shock as Roche’s data disappoints
But biotech still has several hurdles to clear – including Roche’s rival.
Perjeta trial success sends rival biotech’s share price crashing.